Antibiotics For ABS Should Have “Time To Symptom Relief” Trials, FDA Says
Executive Summary
During clinical trials of antibiotics for treating acute bacterial sinusitis, "time to clinical success" is the recommended primary efficacy endpoint, FDA says in new draft guidance on developing ABS drugs